{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037176","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.511756+00:00","generated_at":"2026-06-04T07:18:35.011346+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M","bullets":["Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).","Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.","Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).","Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.","Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037176","json":"https://secwatch.observer/filing/0000950170-24-037176.json","markdown":"https://secwatch.observer/filing/0000950170-24-037176.md","text":"https://secwatch.observer/filing/0000950170-24-037176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/0000950170-24-037176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/pyxs-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:18:35.011346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}